In [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} (Page 592) of the published paper, the columns of the lower and upper limits of 95% confidence of the adjusted OR for the total NTDs should interchange with each other. For example, "**1.98 (3.86--1.02)**" should be "**1.98 (1.02--3.86)**". The columns of the adjusted OR and the lower limit of 95% confidence for anencephaly should interchange with each other. For example, "**0.74 (1.93--5.01)**" should be "**1.93 (0.74--5.01)**". A corrected [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} is included below and the data requiring revision are marked in bold.

###### Risks of Neural Tube Defects (NTDs) in Association with Levels of Polycyclic Aromatic Hydrocarbons (PAHs) above the Median Concentration in Maternal Serum of Controls in Shanxi Province, China, 2010--2013

                                                         total NTDs                      anencephaly                    *spina bifida*                                                                          
  -------- ------------------ -------------------------- ------------------------------- ------------------------------ ----------------------------- ----------------------------- --------------------------- -------------------------
  L-PAHs   ANY                140 (19.8--368)            1.82 (1.08--3.07) \*            **1.98 (1.02--3.86)** \*       1.17 (0.58--2.35)             **1.93 (0.74--5.01)**         1.60 (0.86--2.95)           2.16 (0.95--4.90)
  ACE      194 (58.5--416)    4.25 (2.37--7.62) \*\*\*   **4.50 (2.13--9.51)** \*\*\*    2.37 (1.12--5.04) \*           **4.38 (1.44--13.28)** \*\*   3.70 (1.83--7.47) \*\*\*      3.84 (1.57--9.40) \*\*      
  FLE      588 (204--1333)    2.50 (1.46--4.29) \*\*     **2.84 (1.44--5.62)** \*\*      2.12 (1.01--4.45) \*           **3.14 (1.13--8.74)** \*      1.95 (1.04--3.65) \*          2.15 (0.97--4.79)           
  PHE      1051 (404--2396)   2.40 (1.41--4.10) \*\*     **2.99 (1.51--5.91)** \*\*      1.37 (0.68--2.77)              **2.25 (0.86--5.87)**         1.89 (1.01--3.54) \*          2.01 (0.91--4.45)           
  ANT      95.4 (45.1--194)   7.87 (4.00--15.5) \*\*\*   **8.53 (3.77--19.29)** \*\*\*   4.87 (2.01--11.8) \*\*\*       **6.45 (1.96--21.21)** \*\*   7.89 (3.34--18.7) \*\*\*      7.91 (2.83--22.11) \*\*\*   
  FLU      199 (42.8--462)    2.70 (1.57--4.64) \*\*\*   **3.36 (1.68--6.71)** \*\*\*    1.67 (0.82--3.39)              **3.48 (1.25--9.64)** \*      2.59 (1.36--4.95) \*\*        2.25 (1.00--5.05)           
  RET      378 (109--787)     2.20 (1.30--3.73) \*\*     **2.30 (1.16--4.53)** \*        1.29 (0.64--2.59)              **1.44 (0.57--3.66)**         2.09 (1.11--3.94) \*          1.78 (0.79--4.04)           
                                                                                                                                                                                                                
  H-PAHs   PYR                289 (120--658)             2.40 (1.41--4.10) \*\*          **2.31 (1.16--4.60)** \*       1.78 (0.87--3.65)             **3.10 (1.09--8.88)** \*      2.16 (1.15--4.08) \*        2.11 (0.93--4.78)
  BAA      92.4 (30.1--190)   3.23 (1.86--5.63) \*\*\*   **3.17 (1.56--6.46)** \*\*      2.42 (1.16--5.08) \*           **3.60 (1.28--10.11)** \*     4.22 (2.09--8.53) \*\*\*      4.41 (1.76--11.05) \*\*     
  CHR      106 (24.3--285)    2.82 (1.64--4.86) \*\*\*   **3.08 (1.51--6.26)** \*\*      1.72 (0.84--3.53)              **2.93 (1.07--8.01)** \*      2.62 (1.36--5.05) \*\*        2.84 (1.19--6.77) \*        
  BBF      71.2 (0--143)      2.11 (1.25--3.58) \*\*     **2.40 (1.21--4.75)** \*        1.72 (0.85--3.50)              **3.44 (1.23--9.62)** \*      2.31 (1.23--4.35) \*\*        2.22 (0.98--5.00)           
  BKF      19.8 (0--69.0)     1.97 (1.16--3.32) \*       **2.56 (1.28--5.11)** \*\*      1.67 (0.82--3.39)              **3.36 (1.20--9.39)** \*      2.08 (1.11--3.90) \*          2.65 (1.15--6.09) \*        
  BAP      36.4 (7.90--147)   2.48 (1.45--4.24) \*\*\*   **2.46 (1.22--4.93)** \*        3.15 (1.46--6.81) \*\*         **1.79 (0.68--4.70)**         3.09 (1.60--5.95) \*\*\*      2.83 (1.18--6.76) \*        
                                                                                                                                                                                                                
           ΣL-PAHs            2851 (1307--6683)          2.61 (1.52--4.49) \*\*\*        **2.91 (1.45--5.83)** \*\*\*   1.72 (0.84--3.53)             **2.59 (0.95--7.07)**         2.09 (1.11--3.94) \*        2.00 (0.89--4.49)
           ∑H-PAHs            805 (420--1514)            4.65 (2.57--8.40) \*\*\*        **5.89 (2.72--12.75)** \*\*    2.76 (1.28--5.96) \*\*        **4.42 (1.48--13.19)** \*\*   4.69 (2.24--9.81) \*\*\*    4.31 (1.71--10.88) \*\*
           ∑PAHs              3656 (1805--8294)          2.95 (1.71--5.09) \*\*\*        **3.24 (1.55--6.80)** \*\*     2.20 (1.05--4.60) \*          **3.76 (1.31--10.77)** \*     2.16 (1.15--4.08) \*        2.29 (1.01--5.17) \*

OR, odds ratio; IQR, interquartile range; \* *p* \< 0.05, \*\* *p* \< 0.01, and \*\*\* *p* \< 0.001.

The abbreviations of individual PAHs are acenaphthylene (ACY), acenaphthene (ACE), fluorene (FLE), phenanthrene (PHE), anthracene (ANT), fluoranthene (FLU), retene (RET), pyrene (PYR), benz\[a\]anthracene (BAA), chrysene (CHR), benzo\[b\]fluoranthene (BBF), benzo\[k\]fluoranthene (BKF), benzo\[a\]pyrene (BAP). ∑L-PAHs is the sum of ANY, ACE, FLE, PHE, ANT, FLU, and RET; ∑H-PAHs of PYR, BAA, CHR, BBF, BKF and BAP; ∑PAHs of ∑L-PAHs and ∑H-PAHs.

Statistical results of all subjects.

Calculated by using binary logistic regression.

Adjust for maternal general characteristics and exposure, including BMI, parity, fever of flu during early pregnancy, and active or passive smoking and drinking.
